Skip to main content


Details of the Drug
Generic Name:
oh-bi-nue-tooz-ue mab
Drug Type:
Monoclonal antibody
How the Drug is Given:

Intravenously (IV)


Indications and Usage

Obinutuzumab is FDA-approved 

  • In combination with​ chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
  • In combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.
  • In combination with chemotherapy followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.

Side effects needing medical attention

Infusion-related reactions during the first infusion; low platelet count; low red blood cell counts; fever; cough; muscle and joint pain; low count of certain types of white blood cells.

Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, has been reported with obinutuzumab.

Hepatitis B virus (HBV) reactivation may cause serious liver problems including liver failure and death. If patients have had hepatitis B or are carriers of HBV, receiving obinutuzumab could cause the virus to become an active infection again.  

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.